Timothy A. Springer net worth and biography

Timothy Springer Biography and Net Worth

Director of Cartesian Therapeutics

Timothy A. Springer, Ph.D., has served as a member of our board of directors since June 2016 and as a scientific advisor to us since December 2008. Dr. Springer has most recently served as the Latham Family Professor at Harvard Medical School. Dr. Springer was the founder of LeukoSite, a biotechnology company acquired by Millennium Pharmaceuticals in 1999. Dr. Springer is a member of the National Academy of Sciences and his honors include the Crafoord Prize, the American Association of Immunologists Meritorious Career Award, the Stratton Medal from the American Society of Hematology, and the Basic Research Prize from the American Heart Association. Dr. Springer received his PhD from Harvard University.

What is Timothy A. Springer's net worth?: The estimated net worth of Timothy A. Springer is at least $29.79 million as of April 9th, 2025. Dr. Springer owns 4,317,276 shares of Cartesian Therapeutics stock worth more than $29,789,204 as of December 5th. This net worth evaluation does not reflect any other assets that Dr. Springer may own. Learn More about Timothy A. Springer's net worth.
How do I contact Timothy A. Springer?: The corporate mailing address for Dr. Springer and other Cartesian Therapeutics executives is 65 Grove Street, Watertown, MA 02472, United States. Cartesian Therapeutics can also be reached via phone at 617-923-1400 and via email at [email protected]. Learn More on Timothy A. Springer's contact information.
Has Timothy A. Springer been buying or selling shares of Cartesian Therapeutics?: Timothy A. Springer has not been actively trading shares of Cartesian Therapeutics during the last quarter. Most recently, on Friday, October 4th, Timothy A. Springer bought 80,301 shares of Cartesian Therapeutics stock. The stock was acquired at an average cost of $22.58 per share, with a total value of $1,813,196.58. Following the completion of the transaction, the director now directly owns 8,023,766 shares of the company's stock, valued at $181,176,636.28. Learn More on Timothy A. Springer's trading history.
Who are Cartesian Therapeutics' active insiders?: Cartesian Therapeutics' insider roster includes Blaine Davis (CFO), Miloš Miljković (Chief Medical Officer), and Timothy Springer (Director). Learn More on Cartesian Therapeutics' active insiders.
Are insiders buying or selling shares of Cartesian Therapeutics?: During the last year, insiders at the sold shares 6 times. They sold a total of 14,744 shares worth more than $247,337.42. The most recent insider tranaction occured on January, 6th when CTO Metin Kurtoglu sold 2,458 shares worth more than $41,368.14. Insiders at Cartesian Therapeutics own 60.3% of the company. Learn More about insider trades at Cartesian Therapeutics.
Information on this page was last updated on 1/6/2025.

Timothy A. Springer Insider Trading History at Cartesian Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/4/2024	Buy	80,301	$22.58	$1,813,196.58	8,023,766
10/2/2024	Buy	5,514	$17.38	$95,833.32	7,823,559
8/12/2024	Buy	8,016	$12.72	$101,963.52	11,509
3/18/2024	Buy	634	$18.00	$11,412.00	1,035,780
3/14/2024	Buy	21,612	$16.20	$350,114.40	1,017,228
3/11/2024	Buy	40	$19.50	$780.00	3,213
3/8/2024	Buy	160	$19.80	$3,168.00	3,173
2/6/2024	Buy	26	$19.50	$507.00	2,933
1/17/2024	Buy	26	$20.70	$538.20	2,907

Timothy A. Springer Buying and Selling Activity at Cartesian Therapeutics

Cartesian Therapeutics Company Overview

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

Today's Range

Now: $6.90

$6.53

$7.00

50 Day Range

MA: $8.43

$6.65

$10.34

2 Week Range

Now: $6.90

$5.98

$26.50

Volume

364,771 shs

Average Volume

129,291 shs

Market Capitalization

$179.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.36